Tech Company Financing Transactions

Viamet Pharmaceuticals Funding Round

Viamet Pharmaceuticals closed a $60 million Series D funding round on 10/21/2014. Investors included Astellas Venture Capital, Brandon Capital Partners and Hatteras Venture Partners.

Transaction Overview

Company Name
Viamet Pharmaceuticals
Announced On
10/21/2014
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series D
Investors

Astellas Venture Capital

Brandon Capital Partners (Adrian Howd)

Hatteras Venture Partners (Douglas Reed)

Intersouth Partners (James Rosen)

Lilly Ventures (Edward Torres)

Lurie Investments

Novartis Venture Fund (Lauren Silverman)

Woodford Investment Management

Proceeds Purpose
l compounds, as well as to initiate new research programs supported by the company's Metallophile® platform. The financing is expected to provide sufficient capital to fund operations through the achievement of several important clinical milestones over the next number of years.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4505 Emperor Blvd. 300
Durham, NC 27703
USA
Phone
(919) 467-8539
Website
www.viamet.com
Email Address
Not Recorded
Overview
Viamet Pharmaceuticals discovers and develops best-in-class inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile Technology.
Profile
Viamet Pharmaceuticals LinkedIn Company Profile
Social Media
Viamet Pharmaceuticals Company Twitter Account
Company News
Viamet Pharmaceuticals News
Facebook
Viamet Pharmaceuticals on Facebook
YouTube
Viamet Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Schotzinger
  Robert Schotzinger LinkedIn Profile  Robert Schotzinger Twitter Account  Robert Schotzinger News  Robert Schotzinger on Facebook
Chief Medical Officer
Oren Cohen
  Oren Cohen LinkedIn Profile  Oren Cohen Twitter Account  Oren Cohen News  Oren Cohen on Facebook
VP - Product Management
Thorsten Degenhardt
  Thorsten Degenhardt LinkedIn Profile  Thorsten Degenhardt Twitter Account  Thorsten Degenhardt News  Thorsten Degenhardt on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/21/2014: Saylent Technologies venture capital transaction
Next: 10/21/2014: Telcare venture capital transaction

 

Share this article

 

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.